December 2, 2024 PharmaCielo achieved 85% Year-Over-Year Sales Growth, Generating Year-to-Date Q3 Total Revenue of $2.4 Million Q3 Gross Profit Turned Positive Reflecting More Diverse Customer Base Q3 Cash Flow Improved and EBITDA Increased by $0.8 Million Reflecting Strong Sales Growth and Reduced Costs TORONTO
November 5, 2024 All figures in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, November 5, 2024 – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTC: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis
October 7, 2024 All figures in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, October 7, 2024 – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTC: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis
August 16, 2024 All figures in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, August 16, 2024 – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTC: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis